it's fund raising for LJPC.
I know I added by selling some CYTK and OPK, but didn't get ripped off.
how similar are the stories and markets addressed?
2/25 Wedbush - Wedbush initiated coverage on La Jolla Pharma (NASDAQ: LJPC) with an Outperform rating and price target of $27.00. Analyst Liana Moussatos said GCS-100 sales have potential to reach $1 billion.
3/6 Chardan - Chardan Capital Markets initiated coverage on La Jolla Pharma (NASDAQ: LJPC) with a Buy rating and a price target of $32.00.
In the report, analyst Lisa Wang said: "LJPC's leading compounds GCS-100 and LJPC-501 address
unmet medical needs
including chronic kidney disease (CKD) and hepatorenal syndrome (HRS). We believe LJPC shares are significantly undervalued and offer excellent risk/reward ahead of the GCS-100 phase IIa CKD top-line data release this month (upside of over $10/share and limited downside supported by LJPC-501). Additional value drivers include LJPC-501 phase I trial initiation in 1H14 and preliminary data/proof-of-concept potentially by YE14."
that's only half a billion market cap
A blues riff in the key of G
What rhymes with Intercept Pharmaceuticals?
If so 17.4 M @ $15 = 261M market cap.
What are the holes in the story?
Just felt like it - there was this block of resistance @ $24.80 - a repeating 100 share order of unknown depth. Let's go see what $30 feels like.
Added ITMN, NPSP, MYGN, MGNX, XNCR, AERI, BOTA and some LJPC today.